Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Express2 Revises Boston Scientific’s U.S. Stent Sales; Japan Nir Sales Sag

This article was originally published in The Gray Sheet

Executive Summary

Rapid uptake of the Express2 stent confirms Boston Scientific's expectation that the internally developed platform will revitalize its languishing stent business as the company awaits the introduction of a drug-eluting counterpart

You may also be interested in...

Boston Scientific Cuts Medinol Ties With Express2 Stent Approval In U.S.

Boston Scientific will no longer depend on Israeli firm Medinol for its coronary stents in the U.S. after gaining FDA approval of its Express2 stent Sept. 12

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts